Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5582-5591

  Abbosh, Phillip H ^a   Montgomery, John S ^a   Starkey, Jason A ^b   Novotny, Milos ^b   Zuhowski, Eleanor G ^c   Egorin, Merrill J ^c   Moseman, Annie P ^a   Golas, Adam ^a   Brannon, Kate M ^a   Balch, Curtis ^a   Huang, Tim H M ^d   Nephew, Kenneth P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; HISTONE H3; LYSINE; LYSINE 27; PACLITAXEL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL ISOLATION; CHEMOSENSITIVITY; CHROMATIN; CHROMATIN CONDENSATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOSE RESPONSE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATIN; CISPLATIN; CPG ISLANDS; DNA METHYLATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; LYSINE; OVARIAN NEOPLASMS; POINT MUTATION; TUMOR SUPPRESSOR PROTEINS;

EID: 33745228778     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3575     Document Type: Article

References (50)

1. Lewis EB. A gene complex controlling segmentation in Drosophila. Nature 1978;276:565-70.
2. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
3. Otte AP, Kwaks TH. Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? Curr Opin Genet Dev 2003;13:448-54.
4. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A 2005;102:1859-64.
5. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004;14:155-64.
6. Kirmizis A, Hartley SM, Kuzmichev A, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004;18:1592-605.
7. Muller J, Hart CM, Francis NJ, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002;111:197-208.
8. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
9. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
10. Kirmizis A, Hartley SM, Farnham PJ. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003;2:113-21.
11. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
12. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
13. Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001;107:323-37.
14. Tachibana M, Sugimoto K, Nozaki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 2002;16:1779-91.
15. Behrens BC, Hamilton TC, Masuda H, et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987;47:414-8.
16. Levenstein ME, Kadonaga JT. Biochemical analysis of chromatin containing recombinant Drosophila core histones. J Biol Chem 2002;277:8749-54.
17. Stach D, Schmilz OJ, Stilgenbauer S, et al. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003;31:E2.
18. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005;310:306-10.
19. Lehnertz B, Ueda Y, Derijck AA, et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 2003;13:1192-200.
20. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001;414:277-83.
21. Xin Z, Tachibana M, Guggiari M, et al. Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center. J Biol Chem 2003;278:14996-5000.
22. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
23. Strathdee G, MacKean MJ, Illand M, et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.
24. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999;96:214-9.
25. Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476-81.
26. Whiteside MA, Chen DT, Desmond RA, et al. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 2004;23:744-52.
27. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
28. Balch C, Yan P, Craft T, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005;4:1505-14.
29. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-44.
30. Peters AH, Kubicek S, Mechtler K, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell 2003;12:1577-89.
31. 6-benzylguanine. Mol Cancer Ther 2003;2:633-40.
32. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-44.
33. Westerveld A, Hoeijmakers JH, van Duin M, et al. Molecular cloning of a human DNA repair gene. Nature 1984;310:425-9.
34. Parker RJ, Eastman A, Bostick-Bruton F, et al. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991;87:772-7.
35. Friedberg EC, Walker GC, Siede W. DNA repair and mutagenesis. Washington (DC): ASM Press; 1995.
36. Tachibana M, Sugimoto K, Fukushima T, et al. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001;276:25309-17.
37. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280:22437-44.
38. Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004;64:8184-92.
39. Mager J, Montgomery ND, de Villena FP, et al. Genome imprinting regulated by the mouse Polycomb group protein Eed. Nat Genet 2003;33:502-7.
40. Fujii S, Luo RZ, Yuan J, et al. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 2003;12:1791-800.
41. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 2002;62:6456-61.
42. Bachman KE, Park BH, Rhee I, et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003;3:89-95.
43. Espada J, Ballestar E, Fraga MF, et al. Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 2004;279:37175-84.
44. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
45. Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
46. Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004;92:223-37.
47. Marchion DC, Bicaku E, Daud AI, et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005;65:3815-22.
48. Giannattasio M, Lazzaro F, Plevani P, et al. The DNA damage checkpoint response requires histone H2B ubiquitination by Rad6-Brel and H3 methylation by Dot1. J Biol Chem 2005;280:9879-86.
49. Huyen Y, Zgheib O, Ditullio RA, Jr., et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 2004;432:406-11.
50. Sanders SL, Portoso M, Mata J, et al. Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 2004;119:603-14.